PubMed:32603531 / 89-333 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":166,"end":171},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma9576"}],"text":"The aim of this clinical trial was to evaluate the effects of febuxostat (FBX) in comparison with hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest CT findings in outpatients with moderate symptoms of COVID-19 infection."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":166,"end":171},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0001443"}],"text":"The aim of this clinical trial was to evaluate the effects of febuxostat (FBX) in comparison with hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest CT findings in outpatients with moderate symptoms of COVID-19 infection."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T2","span":{"begin":225,"end":233},"obj":"Disease"},{"id":"T3","span":{"begin":234,"end":243},"obj":"Disease"}],"attributes":[{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"The aim of this clinical trial was to evaluate the effects of febuxostat (FBX) in comparison with hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest CT findings in outpatients with moderate symptoms of COVID-19 infection."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T2","span":{"begin":4,"end":7},"obj":"http://purl.obolibrary.org/obo/PR_000001343"},{"id":"T3","span":{"begin":156,"end":161},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T4","span":{"begin":166,"end":171},"obj":"http://www.ebi.ac.uk/efo/EFO_0000965"}],"text":"The aim of this clinical trial was to evaluate the effects of febuxostat (FBX) in comparison with hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest CT findings in outpatients with moderate symptoms of COVID-19 infection."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":62,"end":72},"obj":"Chemical"},{"id":"T2","span":{"begin":98,"end":116},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_31596"},{"id":"A2","pred":"chebi_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"}],"text":"The aim of this clinical trial was to evaluate the effects of febuxostat (FBX) in comparison with hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest CT findings in outpatients with moderate symptoms of COVID-19 infection."}

{"project":"LitCovid-sentences","denotations":[{"id":"T4","span":{"begin":0,"end":244},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The aim of this clinical trial was to evaluate the effects of febuxostat (FBX) in comparison with hydroxychloroquine (HCQ) on clinical symptoms, laboratory tests and chest CT findings in outpatients with moderate symptoms of COVID-19 infection."}